Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

2026-02-12 - 23:25

ATI-1701 – Biodefense Vaccine Candidate Achieves Key Manufacturing and Scientific Milestones Read More